Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 60/100

Failure Rate

14.3%

1 terminated/withdrawn out of 7 trials

Success Rate

75.0%

-11.5% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

33%

1 of 3 completed trials have results

Key Signals

1 recruiting1 with results

Enrollment Performance

Analytics

N/A

4(66.7%)

Phase 1

1(16.7%)

Phase 2

1(16.7%)

6Total

N/A(4)

Phase 1(1)

Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT04337255Not ApplicableActive Not Recruiting

Mediterranean-DASH Intervention for Neurodegenerative Delay (MIND) Diet in Stroke Patients Patients

Role: collaborator

NCT06907485Phase 2Not Yet Recruiting

A Multicenter Study to Assess the Feasibility of 5-Aminolevulinic Acid (5-ALA) in Pediatric Brain Tumor Patients

Role: collaborator

NCT06538571Not ApplicableRecruiting

Association of Near Infrared Spectroscopy With Interstage Outcomes

Role: lead

NCT00441792Not ApplicableCompleted

The Effect of Etomidate on Patient Outcomes After Single Bolus Doses

Role: lead

NCT00676598Completed

A Prospective Analysis of the Effect of Therapeutic Hypothermia After Cardiac Arrest

Role: lead

NCT00938990Not ApplicableWithdrawn

The Effect of Etomidate on Outcomes of Trauma Patients

Role: lead

NCT00671710Phase 1Completed

Study of Aminolevulinic Acid to Enhance Visualization and Resection of Malignant Glial Tumors of the Brain

Role: lead

All 7 trials loaded